How it works Clinical evidence Comparison with other GLP-1s Market outlook References Further reading Orforglipron, the first promising oral small-molecule GLP-1, is demonstrating weight-loss and metabolic results that could reshape obesity treatment and challenge injectable standards
We hypothesize that adding a long-acting GLP-1-RA can increase basal GLP-1 levels and, in combination with native post-prandial GLP-1 bolus restored after MBS, may be considered as a basal-bolus treatment for individuals with MBS failure (Fig
Fornes, A., Huff, J., Pritchard, R
Symptoms I Pay Attention To Unusual fatigue Rapid heart rate New digestive issues Anxiety or restlessness Drastic changes in hunger Red Flags Patients Often Ignore Feeling extremely cold Consistent brain fog Dramatic hair shedding No weight loss after 12+ weeks These can signal dose adjustments for thyroid medication, not a problem with GLP-1
Patel A, Torre B, Young B, et al
The training covers obesity science, nutritional interventions, pharmacotherapy, and behavioral strategies solidifying the legitimacy of psychiatrists treating weight as part of holistic care
